Compare Stocks: SALV, PYC, and COT

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COT Cotinga Pharmaceuticals Inc. (COT.V)	C$0.04 -41.7%	C$0.03	C$0.02 ▼ C$0.12	C$770K	N/A	20,281 shs	1,000 shs

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COT Cotinga Pharmaceuticals Inc. (COT.V)	0.00%	0.00%	0.00%	0.00%	0.00%

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COT Cotinga Pharmaceuticals Inc. (COT.V)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COT Cotinga Pharmaceuticals Inc. (COT.V)	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COT Cotinga Pharmaceuticals Inc. (COT.V)	N/A	N/A	C$0.00 per share	17.50	C($0.18) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COT Cotinga Pharmaceuticals Inc. (COT.V)	N/A	-C$0.12	N/A	∞	N/A	N/A	N/A	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COT Cotinga Pharmaceuticals Inc. (COT.V)	C$0.24	685.71%	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COT Cotinga Pharmaceuticals Inc. (COT.V)	N/A	0.05	0.01

Ownership

Institutional Ownership

Company	Institutional Ownership
COT Cotinga Pharmaceuticals Inc. (COT.V)	N/A

Insider Ownership

Company	Insider Ownership
COT Cotinga Pharmaceuticals Inc. (COT.V)	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
COT Cotinga Pharmaceuticals Inc. (COT.V)	N/A	21.99 million	N/A	Not Optionable

SALV, PYC, and COT Headlines

Source	Headline
	Lexicon Pharmaceuticals Inc. wsj.com - February 14 at 2:28 PM
	Acumen Pharmaceuticals Inc ABOS morningstar.com - November 5 at 5:44 AM
	SXTP 60 Degrees Pharmaceuticals, Inc. seekingalpha.com - July 22 at 12:42 AM
	8-K: ENANTA PHARMACEUTICALS INC marketwatch.com - April 28 at 8:42 AM
	Ironwood Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call Presentation seekingalpha.com - February 18 at 2:25 PM
	PTPI Petros Pharmaceuticals, Inc. seekingalpha.com - January 24 at 12:37 PM
	Bexion Pharmaceuticals, Inc. Announces First Patient Dosed with BXQ-350 in the ASIST Clinical Study ksn.com - January 12 at 10:28 AM
	Amylyx Pharmaceuticals Inc. wsj.com - October 11 at 1:58 PM
	PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate Developments yahoo.com - August 12 at 8:43 AM
	Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference finance.yahoo.com - May 26 at 4:14 PM

Company Descriptions

Cotinga Pharmaceuticals Inc. (COT.V)

CVE:COT

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.

Compare Stocks